Depth of Response Correlates with Improved Outcomes for Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone

AFFECTION_STATUS - Affection status for smoldering multiple myeloma (phv00555628.v1.p1)

ANALYTE_TYPE - Analyte type (phv00555635.v1.p1)
BIOCHEMICAL_PROGRESSION - Index of biochemical progression events (phv00555629.v1.p1)
BODY_SITE - Body site where sample was collected (phv00555634.v1.p1)
COMMENT1 - Library Type (phv00555641.v1.p1)
COMMENT2 - 10x Kit version (phv00555642.v1.p1)
CONSENT - Type of consent (phv00555623.v1.p1)
HISTOLOGICAL_TYPE - Histological type (phv00555637.v1.p1)
IS_TUMOR - Tumor status (phv00555636.v1.p1)
SAMPLE_ID - Sample ID (phv00555633.v1.p1)
SAMPLE_ID - Sample ID (phv00555626.v1.p1)
SLIM_CRAB_PROGRESSION - Index of overt myeloma progression events (phv00555630.v1.p1)
SUBJECT_ID - Subject ID (phv00555627.v1.p1)
SUBJECT_ID - Subject ID (phv00555622.v1.p1)
SUBJECT_ID - Subject ID (phv00555625.v1.p1)
TIMEPOINT - Timepoint at time of collection (phv00555639.v1.p1)
TUMOR_STAGE - Stage of disease (phv00555640.v1.p1)